LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

InflaRx NV

Fermé

0.84 2.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.81

Max

0.85

Chiffres clés

By Trading Economics

Revenu

-3.2M

-8.3M

BPA

-0.13

Marge bénéficiaire

1,208,456.738

Employés

74

EBITDA

-3.2M

-8.2M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+585.88% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-54M

60M

Ouverture précédente

-1.6

Clôture précédente

0.84

Score Technique

By Trading Central

Confiance

Bearish Evidence

InflaRx NV Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 juin 2025, 14:31 UTC

Résultats

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 juin 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 juin 2025, 20:33 UTC

Résultats

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 juin 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 juin 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 juin 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 juin 2025, 16:35 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 16:34 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 juin 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 juin 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 juin 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 juin 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 juin 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 juin 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 juin 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 juin 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 juin 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 juin 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 juin 2025, 14:12 UTC

Résultats

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 juin 2025, 14:09 UTC

Résultats

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparaison

Variation de prix

InflaRx NV prévision

Objectif de Prix

By TipRanks

585.88% hausse

Prévisions sur 12 Mois

Moyen 5.83 USD  585.88%

Haut 10 USD

Bas 2 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

6

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.29 / 1.85Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.